Subtopic Deep Dive

Pharmacogenomics of CYP2D6 Poor Metabolizers
Research Guide

What is Pharmacogenomics of CYP2D6 Poor Metabolizers?

Pharmacogenomics of CYP2D6 poor metabolizers examines genetic variants causing reduced CYP2D6 enzyme activity, leading to poor metabolism of drugs like codeine and antidepressants in 7-10% of populations.

CYP2D6 poor metabolizers result from gene deletions, duplications, and inactivating mutations that impair drug metabolism. These variants affect 25% of commonly prescribed drugs including beta-blockers and opioids. Over 500 papers document allele frequencies and clinical guidelines (Gaedigk et al., 2016; Crews et al., 2014).

Curated Papers

Key Challenges

Why It Matters

CYP2D6 genotyping identifies poor metabolizers at risk of codeine toxicity due to absent morphine bioactivation (Crews et al., 2014). In neuropsychopharmacology, TDM combined with genotyping optimizes antidepressant dosing to avoid adverse effects (Hiemke et al., 2017). Population-scale meta-analyses reveal allele distributions guiding global therapy adjustments (Zhou et al., 2017). Tamoxifen efficacy in breast cancer treatment depends on CYP2D6 status for endoxifen production (Borges et al., 2006).

Key Research Challenges

Phenotype Prediction Accuracy

Genotype-to-phenotype translation varies across populations due to allele frequency differences and rare variants. Gaedigk et al. (2016) highlight challenges in diplotypes predicting poor metabolizer status. Activity scores require refinement for ultra-rapid metabolizers.

Standardized Terminology

Inconsistent pharmacogenetic result reporting hinders clinical adoption. Caudle et al. (2016) propose consensus terms for CYP2D6 diplotype-phenotype mapping. Lack of uniformity delays electronic health record integration.

Global Allele Variability

CYP2D6 allele frequencies differ widely, complicating universal guidelines. Zhou et al. (2017) meta-analysis shows population-specific poor metabolizer prevalences from 0.5-10%. Copy number variations add prediction complexity.

Essential Papers

SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules

Antoine Daina, Olivier Michielin, Vincent Zoete · 2017 · Scientific Reports · 15.6K citations

Abstract To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events ...

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

Christoph Hiemke, N. Bergemann, H.‐W. Clement et al. · 2017 · Pharmacopsychiatry · 1.3K citations

Abstract Therapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to optimize pharmacotherapy. It considers the interindividual variability of phar...

Inheritance and Drug Response

Richard M. Weinshilboum · 2003 · New England Journal of Medicine · 1.0K citations

he promise of pharmacogenetics, the study of the role of in heritance in the individual variation in drug response, lies in its potential to identify the right drug and dose for each patient. Even ...

Cytochrome P450 Enzymes and Drug Metabolism in Humans

Mingzhe Zhao, Jingsong Ma, Mo Li et al. · 2021 · International Journal of Molecular Sciences · 850 citations

Human cytochrome P450 (CYP) enzymes, as membrane-bound hemoproteins, play important roles in the detoxification of drugs, cellular metabolism, and homeostasis. In humans, almost 80% of oxidative me...

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

Kristine R. Crews, Andrea Gaedigk, Henry M. Dunnenberger et al. · 2014 · Clinical Pharmacology & Therapeutics · 669 citations

Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms a...

Opioid Metabolism

Howard S. Smith · 2009 · Mayo Clinic Proceedings · 637 citations

Worldwide Distribution of Cytochrome P450 Alleles: A Meta‐analysis of Population‐scale Sequencing Projects

Yitian Zhou, Magnus Ingelman‐Sundberg, Volker M. Lauschke · 2017 · Clinical Pharmacology & Therapeutics · 563 citations

Genetic polymorphisms in cytochrome P450 (CYP) genes can result in altered metabolic activity toward a plethora of clinically important medications. Thus, single nucleotide variants and copy number...

Reading Guide

Foundational Papers

Start with Weinshilboum (2003) for pharmacogenetics principles (1020 citations), then Crews et al. (2014) for CYP2D6-codeine guidelines, and Nebert et al. (2013) for CYP family roles.

Recent Advances

Study Gaedigk et al. (2016) for phenotype prediction, Zhou et al. (2017) for allele distributions, and Zhao et al. (2021) for CYP2D6 metabolism overview.

Core Methods

Genotyping via PCR or NGS for alleles; diplotype-to-phenotype scoring (Gaedigk et al., 2016); TDM quantification (Hiemke et al., 2017); in silico tools like SwissADME (Daina et al., 2017).

How PapersFlow Helps You Research Pharmacogenomics of CYP2D6 Poor Metabolizers

Discover & Search

Research Agent uses searchPapers and exaSearch to find CYP2D6 guidelines like 'Prediction of CYP2D6 phenotype from genotype' (Gaedigk et al., 2016), then citationGraph reveals 500+ related works on poor metabolizers, while findSimilarPapers uncovers population-specific allele studies.

Analyze & Verify

Analysis Agent applies readPaperContent to extract diplotype data from Crews et al. (2014), verifies phenotype predictions with verifyResponse (CoVe), and runs PythonAnalysis on allele frequency datasets for statistical prevalence calculations with GRADE grading for evidence strength.

Synthesize & Write

Synthesis Agent detects gaps in codeine therapy guidelines, flags contradictions between population studies, and uses latexEditText with latexSyncCitations to draft reports; Writing Agent compiles with latexCompile and exportMermaid for CYP2D6 metabolism pathway diagrams.

Use Cases

"Calculate CYP2D6 poor metabolizer prevalence in European vs Asian cohorts using published allele data."

Research Agent → searchPapers('CYP2D6 allele frequencies') → Analysis Agent → readPaperContent(Zhou et al., 2017) → runPythonAnalysis(pandas aggregation of diplotype frequencies) → researcher gets CSV of prevalence stats with p-values.

"Draft CPIC-style guideline update for CYP2D6 poor metabolizers and SSRIs."

Synthesis Agent → gap detection on Hiemke et al. (2017) → Writing Agent → latexEditText(draft guideline) → latexSyncCitations(Crews et al., 2014) → latexCompile → researcher gets PDF guideline with synced references.

"Find GitHub repos analyzing CYP2D6 genotype simulation models from recent papers."

Research Agent → citationGraph(Gaedigk et al., 2016) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets repo code for phenotype simulation with README summaries.

Automated Workflows

Deep Research workflow conducts systematic review of 50+ CYP2D6 papers: searchPapers → citationGraph → readPaperContent → GRADE grading → structured report on poor metabolizer risks. DeepScan applies 7-step analysis with CoVe checkpoints to verify codeine guideline updates from Crews et al. (2014). Theorizer generates hypotheses on CYP2D6 inhibitor interactions from Zhao et al. (2021).

Try Doxa for Pharmacogenomics of CYP2D6 Poor Metabolizers Research

Frequently Asked Questions

What defines a CYP2D6 poor metabolizer?

Poor metabolizers have two nonfunctional CYP2D6 alleles (activity score 0), causing negligible enzyme activity and drug accumulation (Gaedigk et al., 2016).

What methods predict CYP2D6 phenotypes?

Diplotypes from genotyping are mapped to phenotypes using standardized activity scores; CPIC guidelines detail assignments (Crews et al., 2014; Caudle et al., 2016).

What are key papers on CYP2D6 poor metabolizers?

Crews et al. (2014) provides codeine guidelines (669 citations); Gaedigk et al. (2016) predicts phenotypes across populations (496 citations); Zhou et al. (2017) maps global alleles (563 citations).

What open problems exist in CYP2D6 pharmacogenomics?

Refining phenotype predictions for rare alleles and copy number variants; integrating into routine TDM; addressing population variability (Gaedigk et al., 2016; Zhou et al., 2017).